MIR544B: A Potential Drug Target and Biomarker (G100422864)

Target Name: MIR544B

NCBI ID: G100422864

MIR544B

Other Name(s): MicroRNA 544b | hsa-mir-544b | microRNA 544b | hsa-miR-544b

MIR544B: A Potential Drug Target and Biomarker

Mir544B, also known as CD28, is a cell adhesion molecule that plays a critical role in the regulation of T cell responses and has been identified as a potential drug target in cancer. Its unique structure and function make it an attractive target for drug development, particularly for breast cancer.

Mir544B is a transmembrane protein that is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract. Its primary function is to interact with the protein PD-L1, which is a negative regulator of T cell responses. Mir544B has been shown to promote the expression of T cell activation markers, such as the Ki67 enzyme, and to inhibit the expression of PD-L1.

One of the key challenges in the development of cancer therapies is the difficulty of targeting the diverse range of cancer cells that exist. Mir544B's transmembrane structure and its ability to interact with multiple proteins make it an ideal candidate for drug targeting. Its unique function as a regulator of T cell responses also makes it a promising biomarker for cancer diagnosis and treatment.

In addition to its potential as a drug target, Mir544B has also been shown to be a potential biomarker for cancer. Its expression has been found to be significantly increased in a variety of cancer types, including breast cancer. Furthermore, studies have shown that Mir544B has been associated with poor prognosis in patients with breast cancer.

The potential drug target for Mir544B is the use of small molecules, such as inhibitors of PD-L1 activity, to stimulate T cell responses and promote the growth of cancer cells. One approach to drug development for Mir544B is to test the efficacy of small molecules as a treatment for breast cancer by using cell-based assays and animal models of the disease.

Another approach to drug development for Mir544B is to use it as a biomarker to predict the response of cancer cells to different therapies. This can be done by using techniques such as liquid chromatography and mass spectrometry to detect changes in Mir544B expression levels in response to different treatments.

Overall, Mir544B is a promising drug target and biomarker for cancer. Its unique structure and function make it an attractive candidate for drug development, and its potential as a biomarker for cancer diagnosis and treatment is an additional advantage. Further research is needed to fully understand the potential of Mir544B as a drug target and biomarker for cancer.

Protein Name: MicroRNA 544b

The "MIR544B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR544B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets